REGULATORY PERSPECTIVE FOR GENE THERAPY PRODUCTS IN THE USA, EU AND JAPAN AND FUTURE ASPECTS
DOI:
https://doi.org/10.22159/ijpps.2024v16i6.50806Keywords:
Gene therapy products, Medical treatments, Genetic expressions, Regulatory considerations, Regulatory landscapeAbstract
Gene Therapy Products (GTPs) hold immense promise in revolutionizing medical treatments by altering genetic expressions to address various diseases. This study gives a summary of gene therapy products and their prospective uses, their historical development and several treatment options, as an in-depth exploration of the regulatory considerations for GTPs in the United States of America (USA), European Union (EU), and Japan, along with insights into future aspects of this field. A comprehensive discussion follows detailing the regulatory landscape and approval pathways in the USA, EU, and Japan. Programs that are exclusive to each area such as PRIME (Priority Medicines) in the EU, USA's RMAT (Regenerative Medicines Advanced Therapy) designation and the Sakigake system in Japan are examined. Milestone meetings, approval requirements, and specific regulatory guidelines for GTPs in each region are also thoroughly covered. A list of approved GTPs and a glimpse into the future of the field. Anticipated trends include increasing investments, challenges related to production costs, expansion of manufacturing capabilities, and regulatory updates. The various regulatory strategies in each area and their efforts to balance patient access and safety will have a big impact on GTPs marketed in the future. Japan is well-positioned to maintain it’s as a global leader in regenerative medicine and cell treatments because of its favourable regulatory environment and government backing.
Downloads
References
What is Gene Therapy? | FDA [Internet]. [cited 2023 Jul 25]. Available from: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/what-gene-therapy
Genetic Therapies - Benefits and Risks | NHLBI, NIH [Internet]. [cited 2023 Aug 15]. Available from: https://www.nhlbi.nih.gov/health/genetic-therapies/benefits-risks
The Cost of Sequencing a Human Genome [Internet]. [cited 2023 Aug 7]. Available from: https://www.genome.gov/about-genomics/fact-sheets/Sequencing-Human-Genome-cost
Celec P, Gardlik R. Gene therapy using bacterial vectors. Front Biosci (Landmark Ed) [Internet]. 2017 Jan 1 [cited 2023 Jul 25];22(1):81–95. Available from: https://pubmed.ncbi.nlm.nih.gov/27814603/
Soofiyani SR, Baradaran B, Lotfipour F, Kazemi T, Mohammadnejad L. Gene Therapy, Early Promises, Subsequent Problems, and Recent Breakthroughs. Adv Pharm Bull [Internet]. 2013 [cited 2023 Aug 15];3(2):249. Available from: /pmc/articles/PMC3848228/
How to Navigate Global Regulatory Frameworks & Expedited Programs for Gene Therapy Development in the U.S., EU, & Japan > Premier Research [Internet]. [cited 2023 Aug 15]. Available from: https://premier-research.com/blog-how-to-navigate-global-regulatory-frameworks-expedited-programs-for-gene-therapy-development-in-the-u-s-eu-japan/
Fast Track Designation Request Performance | FDA [Internet]. [cited 2023 Jul 25]. Available from: https://www.fda.gov/about-fda/center-biologics-evaluation-and-research-cber/fast-track-designation-request-performance
Breakthrough Therapy | FDA [Internet]. [cited 2023 Jul 25]. Available from: https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/breakthrough-therapy
Vaggelas A, Seimetz D. Expediting Drug Development: FDA’s New Regenerative Medicine Advanced Therapy Designation. Ther Innov Regul Sci [Internet]. 2019 May 1 [cited 2023 Aug 15];53(3):364–73. Available from: https://pubmed.ncbi.nlm.nih.gov/29895180/
Designating an Orphan Product: Drugs and Biological Products | FDA [Internet]. [cited 2023 Aug 15]. Available from: https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/designating-orphan-product-drugs-and-biological-products
Heard JM, Vrinten C, Schlander M, Bellettato CM, Van Lingen C, Scarpa M, et al. Availability, accessibility and delivery to patients of the 28 orphan medicines approved by the European Medicine Agency for hereditary metabolic diseases in the MetabERN network. Orphanet J Rare Dis [Internet]. 2020 Jan 6 [cited 2023 Jul 25];15(1). Available from: https://www.raps.org/News-and-Articles/News-Articles/2023/6/Market-exclusivity-for-orphan-drugs-in-the-US-and
Risk Evaluation and Mitigation Strategies | REMS | FDA [Internet]. [cited 2023 Aug 15]. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/risk-evaluation-and-mitigation-strategies-rems
Postmarketing Requirements and Commitments: Reports | FDA [Internet]. [cited 2023 Aug 16]. Available from: https://www.fda.gov/drugs/postmarket-requirements-and-commitments/postmarketing-requirements-and-commitments-reports
Eichler HG, Pignatti F, Schwarzer-Daum B, Hidalgo-Simon A, Eichler I, Arlett P, et al. Randomized Controlled Trials Versus Real World Evidence: Neither Magic Nor Myth. Clin Pharmacol Ther [Internet]. 2021 May 1 [cited 2023 Jul 26];109(5):1212–8. Available from: https://www.ema.europa.eu/en/human-regulatory/overview/advanced-therapy-medicinal-products-overview
Eichler HG, Pignatti F, Schwarzer-Daum B, Hidalgo-Simon A, Eichler I, Arlett P, et al. Randomized Controlled Trials Versus Real World Evidence: Neither Magic Nor Myth. Clin Pharmacol Ther [Internet]. 2021 May 1 [cited 2023 Aug 7];109(5):1212–8. Available from: https://www.ema.europa.eu/en/human-regulatory/overview/advanced-therapy-medicinal-products-overview
Sakurai A. Pharmaceuticals and Medical Devices Agency Regenerative Medicine and Gene Therapy in Japan Pharmaceuticals and Medical Devices Agency (PMDA)/ Q5A(R2) EWG Deputy Topic Leader (MHLW/PMDA).
PRIME: priority medicines | European Medicines Agency [Internet]. [cited 2023 Jul 25]. Available from: https://www.ema.europa.eu/en/human-regulatory/research-development/prime-priority-medicines
(PDF) Gene therapy. Principles and potential applications [Internet]. [cited 2023 Jul 25]. Available from: https://www.researchgate.net/publication/11647636_Gene_therapy_Principles_and_potential_applications
Azuma K. Regulatory Landscape of Regenerative Medicine in Japan. Curr Stem Cell Rep [Internet]. 2015 Jun 1 [cited 2023 Jul 25];1(2):118–28. Available from: https://link.springer.com/article/10.1007/s40778-015-0012-6
Maeda D, Yamaguchi T, Ishizuka T, Hirata M, Takekita K, Sato D. Regulatory Frameworks for Gene and Cell Therapies in Japan. Adv Exp Med Biol [Internet]. 2015 Sep 19 [cited 2023 Jul 25];871:147–62. Available from: https://pubmed.ncbi.nlm.nih.gov/26374217/
Tanaka M, Idei M, Sakaguchi H, Kato R, Sato D, Sawanobori K, et al. Achievements and challenges of the Sakigake designation system in Japan. Br J Clin Pharmacol. 2021 Oct 1;87(10):4027–35.
Strategy of SAKIGAKE [Internet]. [cited 2023 Jul 25]. Available from: https://www.mhlw.go.jp/english/policy/health-medical/pharmaceuticals/140729-01.html
Sato Y, Ono S. Regulatory Environment and Approvals in Cell and Gene Therapy Products Between Japan, the USA, and the EU. Ther Innov Regul Sci [Internet]. 2023 Mar 1 [cited 2023 Aug 15];57(2):227–37. Available from: https://link.springer.com/article/10.1007/s43441-022-00455-4
Sato Y, Ono S. Regulatory Environment and Approvals in Cell and Gene Therapy Products Between Japan, the USA, and the EU. Ther Innov Regul Sci [Internet]. 2023 Mar 1 [cited 2023 Aug 15];57(2):227–37. Available from: https://pubmed.ncbi.nlm.nih.gov/36112305/
Zhang J. Regulatory Considerations to Accelerate Cell & Gene Therapy Development.
OTP Type A Meetings | FDA [Internet]. [cited 2023 Aug 16]. Available from: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/otp-type-meetings
Fda, Cder. Guidance for Industry Formal Meetings Between the FDA and Sponsors or Applicants. 2009 [cited 2023 Aug 13];301–796. Available from: http://www.fda.gov/cder/guidance/index.htmorhttp://www.fda.gov/cber/guidelines.htm
Manufacturing Changes and Comparability for Human Cellular and Gene Therapy Products | FDA [Internet]. [cited 2023 Jul 25]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/manufacturing-changes-and-comparability-human-cellular-and-gene-therapy-products
Step. Committee for Medicinal Products for Human Use ICH S12 Guideline on nonclinical biodistribution considerations for gene therapy products ICH S12 Guideline on nonclinical biodistribution considerations for gene therapy products. 2023 [cited 2023 Jul 25]; Available from: www.ema.europa.eu/contact
Medicines Agency E. Committee for Medicinal Products for Human Use ICH guideline S12 on nonclinical biodistribution considerations for gene therapy products. 2021 [cited 2023 Jul 25]; Available from: www.ema.europa.eu/contact
Maeda H. The Current Status and Future Direction of Clinical Research in Japan From a Regulatory Perspective. Front Med (Lausanne) [Internet]. 2021 Jan 13 [cited 2023 Aug 16];8:816921. Available from: /pmc/articles/PMC8792780/
Moriyama Y. Clinical trial notifications and Clinical trial notifications and scientific consultation scientific consultation system in Japan system in Japan.
Provisional Translation (as of April 2023)* Ministry of Health, Labour and Welfare Questions and Answers (Q&A) on Points to Consider for Ensuring the Reliability in Utilization of Data from Registry or Medical Information Database in Applications for Marketing Approval and Re-examination for Regenerative Medical Products.
Approved Cellular and Gene Therapy Products | FDA [Internet]. [cited 2023 Jul 25]. Available from: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products
Gene Therapy Medicinal Products with a valid marketing authorisation - Paul-Ehrlich-Institut [Internet]. [cited 2023 Jul 25]. Available from: https://www.pei.de/EN/medicinal-products/atmp/gene-therapy-medicinal-products/gene-therapy-node.html
Review Reports: Regenerative Medical Products | Pharmaceuticals and Medical Devices Agency [Internet]. [cited 2023 Jul 25]. Available from: https://www.pmda.go.jp/english/review-services/reviews/approved-information/0004.html
Cell & Gene Therapy Manufacturing Services Market Drivers & Opportunities | MarketsandMarkets [Internet]. [cited 2023 Aug 7]. Available from: https://www.marketsandmarkets.com/Market-Reports/cell-gene-therapy-manufacturing-services-market-180609441.html?gclid=CjwKCAjw5remBhBiEiwAxL2M94d_G161UicjoTkJ8yN703GLwEh0LdvS3aB_an30JX1G7qdsHCgAIhoCeFcQAvD_BwE
The Cell And Gene Therapy Sector In 2023: A Wave Is Coming – Are We Ready? :: In Vivo [Internet]. [cited 2023 Aug 7]. Available from: https://invivo.pharmaintelligence.informa.com/IV146781/The-Cell-And-Gene-Therapy-Sector-In-2023-A-Wave-Is-Coming--Are-We-Ready
Cell and Gene Therapies for Rare Disorders Treatment in Japan [Internet]. [cited 2023 Aug 7]. Available from: https://www.delveinsight.com/blog/cell-and-gene-therapies-for-rare-disorders-treatment
Published
How to Cite
Issue
Section
Copyright (c) 2024 BALASUBRAMANYA P. K., SANGITA MISHRA, M. P. VENKATESH
This work is licensed under a Creative Commons Attribution 4.0 International License.
